PRIMARY PREVENTION OF VERRUCA PLANTARIS THROUGH TOPICAL HERBAL AND VITAMIN DERIVATIVE

MARK KEVIN KAUFFMAN DO, FACOFP1, MICHELE MARIE ROTH-KAUFFMAN JD2, PRATEEK KHURANA1, LORRIE SINIBALDI1, AARON WALKOWSKI1, ANDREW APUGLIESE2, JUNAID ESSA1

1Department of Primary Care, Lake Erie College of Osteopathic Medicine, Bradenton, Florida. 2Department of Physician, Gannon University, Ruskin, Florida. Email: mkauffman@lecom.edu

Received: 04 November 2019, Revised and Accepted: 19 March 2020

ABSTRACT

Objective: Verruca plantaris (VP) results from environmental exposure to human papillomavirus causing plantar warts of the foot, resistant to treatment, and high recurrence rates. Current treatment paradigms focus on the treatment of lesions as opposed to primary prophylaxis. We hypothesize that a topical combination of herbal supplement with anti-viral properties and a vitamin derivative* can be used prophylactically to decrease the primary incidence.

Methods: We initiated a double-blinded clinical study with participants (n=282) randomization into control (lotion emollient only) (n=120), treatment (herbal and vitamin derivative) (n=110) and no treatment (NT) (n=52). Participants underwent examination of the feet at baseline (0 months) to exclude VP lesions and were randomized to receive a bottle containing topical lotion with emollient only, control (C) lotion with an herbal and vitamin derivative, treatment (T), or NT, where participants did not apply anything to their feet. C and T participants applied lotion topically to the feet once daily and were examined at 3, 6, 9, and 12 months to document the incidence of VP.

Results: No incidence of VP occurred in the T group (0/110=0% incidence), two lesions in the C group (2/120=1.7% incidence), and five lesions in the NT group (5/52=9.6% incidence).

Conclusion: Treatments for VP rely on treating lesions after they occur, have high degrees of variability in success, risk of continued transmission during treatment, and have high rates of recurrence. Although the study number is relatively low, early indications show decreasing incidence of VP from 9.6% in participants with NT to 1.7% in participants who used lotion only, suggesting increased health of the plantar epidermis, and 0% incidence in those participants applying topical herbal and vitamin derivative*. Additional study with increased numbers of participants is warranted.

Keywords: Verruca plantaris, Human papillomavirus, Plantar wart.
cryotherapy with liquid nitrogen which has been shown to be less effective than salicylic acid [11] and may be associated with mobility-limiting pain [15] and is not recommended for small children. Both may require weeks to months of daily applications and parting of the hyperkeratotic tissues [3,4,8]. With poor treatment outcomes and high rates of recurrence, primary prevention of VP by use of topical anti-viral prophylaxis in high-risk populations coupled with diminishing risk factors and maintenance of the integrity of the epidermal barrier would represent a shift in treatment paradigm moving from the current standard of treating after the occurrence which is often costly and ineffective.

METHODS

We initiated a double-blinded clinical research study consisting of two arms: Control (lotion emollient only) and treatment (herbal and vitamin derivative). The study Group I (SGI) consisted primarily of university age (18–24 years) participants with an attempt to recruit participants with high-risk activities such as participation in sports and communal recreational facility use. Participants underwent an examination of the feet at baseline (0 months) to document the presence of active lesions. Of the 161 participants, 5 had active VP with 5 participants being excluded due to primary VP at enrollment resulting in SGI (n=156). Participants were randomized into one of the two study arms; Green Bottle and Blue Bottle. One bottle contained topical lotion with emollient only control (C) (n=82) and the other a topical lotion with an herbal and vitamin derivative combination treatment (T) (n=74). Participants applied the lotions topically to the feet on a once-daily through metered-dose pumping. Participants were then examined at 3, 6, 9, and 12 months to document the incidence of VP occurrence.

RESULTS

At the conclusion of the 12-month study, no incidence of VP occurred in either the control or treatment groups. Although this study group is relatively small (n=156), 80 (49.7%) participants self-identified with high-risk activities such as locker room use without shoes, swimming, karate, and yoga. With an estimated 14% annual incidence, some incidence of new lesions would be expected [6]. No incidence of new-onset VP in either treatment group suggests that lotion alone may decrease the incidence of VP, likely due to increased integrity of the epidermis. This identified the lack of a study arm with no lotion for comparison. A second study group enrolled 131 participants, of which five were again excluded due to VP at enrollment resulting in study group 2 (SG2) with (n=126). This double-blinded study randomized participants into three study arms: No treatment (NT) (n=52), control (C) (n=38) – lotion emollient only, and treatment (T) (n=36) – herbal and vitamin derivative. NT participants do not apply anything to their feet. At study conclusion, there was no incidence of VP in the T group (0/36=0%), two in the C group (2/38=5.3%), and five in the NT group (5/52=9.6%).

Combined data from SGI and SG2 (n=282) demonstrate no incidence of VP in the T group, herbal and vitamin derivative (0/110=0% incidence), two VP lesions in the C group, emollient only (2/120=1.7% incidence) group, and five VP lesions in the NT group, NT (5/52 = 9.6% incidence) Fig 1.

CONCLUSION

Treatments for Verruca Plantaris have high degrees of variability in success requiring lengthy duration of treatment, risk of continued transmission during treatment, and high rate of recurrence. Current treatment relies on treating lesions after they occur. Although the study number is relatively low (n=282), early indications show decreasing incidence of VP from 9.6% in participants with NT to 1.7% in participants who used lotion only, suggesting increased health of the plantar epidermis, and 0% incidence in those participants applying topical herbal and vitamin derivative*. The herbal and vitamin derivatives used in this study constitute proprietary information.

REFERENCES

1. Krishna SK, Jethwa AS. Human papillomavirus infections in adults and children. Am J Epidemiol Infect Dis 2013;11:9.
2. Tougan BE, Mancini AJ, Mandell JA, Cohen DE, Sanchez MR. Skin conditions in figure skaters, ice-hockey players and speed skaters: Part II cold-induced, infectious and inflammatory dermatoses. Sports Med 2011;41:967-84.
3. Kenny T, Harding M. Warts and Verrucas; 2015. Available from: http://www.patient.info/health/warts-and-verrucas-leaflet. [Last accessed on 2016 Jul 12].
4. Sudhakar GK, Pai V, Pai A, Kamath V. Therapeutic approaches in the management of plantar warts by human papillomaviruses: A review. Asian J Biomed Pharm Sci 2013;3:1-4.
5. Plantar Warts. The American College of Foot and Ankle Orthopedics and Medicine; 2016. Available from: http://www.acfaom.org/information-for-patients/common-conditions/plantar-warts. [Last accessed on 2016 Jul 21].
6. Bruggink SC, Eekhof JA, Egberts PF, van Blijswijk SC, Assendelft WJ, Gussekloo J. Warts transmitted in families and schools: A prospective cohort. Pediatrics 2013;131:928-34.
7. Warts. American Academy of Dermatology: Excellence in Dermatologic Surgery; 2016. Available from: https://www.aad.org/public/diseases/contagious-skin-diseases/warts. [Last accessed on 2016 Jul 22].
8. Watkins P. Identifying and treating plantar warts. Nurs Stand 2006;20:50-4.
9. Lichon V, Khachemoune A. Plantar warts: A focus on treatment modalities. Dermatol Nurs 2007;19:372-5.
10. Sanclemente G, Gill DK. Human papillomavirus molecular biology and pathogenesis. J Eur Acad Dermatol Venereol 2002;16:231-40.
11. Bruggink SC, Gussekloo J, de Koning MN, Feltkamp MC, Bavink NJ, Quint WG, et al. HPV type in plantar warts influences natural course and treatment response: Secondary analysis of a randomised controlled trial. J Clin Virol 2013;57:227-32.
12. Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease association. Rev Med Virol 2016;26:23-22.
13. Sterling JC, Gibbs SS, Hussain H, Mustapa MF, Handfield-Jones SE. British association of dermatologists’ guidelines for the management of cutaneous warts 2014. Br J Dermatol 2014;171:696-712.
14. Newton H. Viral infections of the skin: Clinical features and treatment options. Nurs Stand 2013;27:43-7.
15. Treat cutaneous warts on a case-by-case basis, taking into account patient factors and the available clinical evidence. Drugs Ther Perspec 2012;28:15.